ASXC - Asensus Surgical's robotic system gets CE mark for machine vision feature

• Asensus Surgical ( NYSE: ASXC ) said it received CE Mark for an expansion of machine vision capabilities on its cleared device Intelligent Surgical Unit (ISU).
• The company noted that with this CE Marking, the expanded ISU capabilities are now commercially available in key geographies, including the EU, Japan, and the U.S.
• In addition, this approval included a review of the Senhance Surgical System platform, making Senhance one of the first robotic surgical systems to be approved through the new, more rigorous EU Medical Device Regulation (MDR) process, the company added.
• "Surgeon feedback from the expanded feature set across the U.S. and Japan has been tremendous, and we look forward to partnering with new and existing customers to help bring advanced real-time intraoperative digital tools into operating rooms throughout Europe," said Asensus President and CEO Anthony Fernando.
• ASXC +0.80% to $0.68 premarket Jan. 23

For further details see: